Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$4.31 - 0.15 (3.36%)
Day High:$4.41
Day Low:$4.29
Volume:94,095
02/22/1712:06 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com


 

Recent News

MORE
DateTitle 
Feb 08, 2017CTI BioPharma to Present at the BIO CEO & Investor Conference
SEATTLE, Feb. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the the BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 8:00 a.m. ET/2:00 p.m. CET in New York. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutical company focused on the ac... 
Printer Friendly Version
Jan 24, 2017CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
SEATTLE, Jan. 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Michael A. Metzger has been appointed a Director of CTI BioPharma. Mr. Metzger brings extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years. "We are pleased to welcome Michael to the Board of CTI BioPharma," said Richard Love, Interim President and CEO of CTI BioPharma. "Michael is an accomplished leader and builder of bio... 
Printer Friendly Version
Jan 09, 2017CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
SEATTLE, Jan. 9, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress on its lead programs in addition to key business priorities for 2017. "Throughout 2016 we maintained our commitment to bringing new therapies to patients with unmet medical needs, and were successful in working with the FDA to remove the full clinical hold on pacritinib and get it back on the development track for the benefit of myelofibrosis patients," said Richa... 
Printer Friendly Version

Events

MORE
DateTitle
Feb 14, 2017
CTI BioPharma Corp at BIO CEO and Investor Conference
Data provided by Nasdaq. Minimum 15 minutes delayed.